JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

Kodu・Aktsiate loetelu・CorMedix Inc

CorMedix Inc

Suletud

SektorTervishoid

7.33 -1.87

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

7.3

Max

7.49

Põhinäitajad
By Trading Economics
Sissetulek	-95M 14M
Müük	24M 129M
P/E Sektori keskmine	3.716 60.328
Aktsiakasum	0.16
Kasumimarginaal	10.901
Töötajad	191
EBITDA	9.2M 66M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+76.9% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	5. mai 2026

Turustatistika
By TradingEconomics
Turukapital	31M 599M
Eelmine avamishind	9.2
Eelmine sulgemishind	7.33

Uudiste sentiment

By Acuity

50%

178 / 348 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bullish Evidence

9.2 / N/A Toetus ja vastupanu

CorMedix Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

24. apr 2026, 00:00 UTC

Tulu

Renesas Electronics 1Q Net Y68.15B Vs Net Y26.01B

24. apr 2026, 00:00 UTC

Tulu

Renesas Electronics 1Q Net Y68.15B Vs Net Y26.01B

23. apr 2026, 23:47 UTC

Market Talk

Gold Edges Lower Amid Ongoing Concerns Over Higher Inflation -- Market Talk

23. apr 2026, 23:43 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

23. apr 2026, 23:43 UTC

Market Talk

Global Equities Roundup: Market Talk

23. apr 2026, 23:43 UTC

Market Talk

Nikkei May Decline Amid Uncertainty Over U.S.-Iran Conflict -- Market Talk

23. apr 2026, 23:13 UTC

Omandamised, ülevõtmised, äriostud

Trump on Spirit Airlines: 'I Think We'd Just Buy It' -- Update

23. apr 2026, 22:33 UTC

Tulu

Intel Shares Jump 20% as AI Agents Drive Big Growth -- WSJ

23. apr 2026, 22:17 UTC

Tulu

PLS Executed Offtake Agreement With Ronbay

23. apr 2026, 22:17 UTC

Tulu

PLS Secured Up to A$38.1M in Australia Government ARENA Grant Funding

23. apr 2026, 22:16 UTC

Tulu

PLS Commences Commissioning of Midstream Demonstration Plant

23. apr 2026, 22:15 UTC

Tulu

PLS Group Reaffirms FY26 Guidance for All Metrics

23. apr 2026, 22:14 UTC

Tulu

PLS Group 3Q Cash Margin From Operations A$461M at March 31

23. apr 2026, 22:14 UTC

Tulu

PLS Group 3Q Cash Balance A$1.455 Billion at March 31

23. apr 2026, 22:13 UTC

Tulu

PLS Group 3Q Unit Operating Cost A$733/Ton CIF, Up 2% on 2Q

23. apr 2026, 22:12 UTC

Tulu

Correct: PLS Group 3Q Unit Operating Cost A$520/Ton FOB, Down 11% on 2Q

23. apr 2026, 22:12 UTC

Tulu

PLS Group 3Q Unit Operating Cost US$520/Ton FOB, Down 11% on 2Q

23. apr 2026, 22:11 UTC

Tulu

PLS Group 3Q Realized Price US$1,867/Ton, Up 61% on 2Q

23. apr 2026, 22:10 UTC

Tulu

PLS Group 3Q Revenue A$567,000, Up 52% on 2Q

23. apr 2026, 22:09 UTC

Tulu

PLS Group 3Q Sales 195,700 Tons, Down 16% on 2Q

23. apr 2026, 22:08 UTC

Tulu

PLS Group 3Q Production 232,400 Tons, Up 12% on 2Q

23. apr 2026, 22:04 UTC

Tulu

Intel Sales Rise 7% as AI Agents Drive Growth -- WSJ

23. apr 2026, 21:56 UTC

Market Talk

Tulu

Intel Points to Growing Role of CPUs Amid AI Shifts -- Market Talk

23. apr 2026, 21:48 UTC

Omandamised, ülevõtmised, äriostud

Regeneron Shares Up on Trump Drug Pricing Deal -- Barrons.com

23. apr 2026, 21:27 UTC

Tulu

Intel CFO: All Demand Signals Point to Growing Role of CPUs in AI Era

23. apr 2026, 21:25 UTC

Tulu

Intel CFO Expects Factories to Continue Increasing Supply in 3Q, 4Q, but at More Measured Pace Than Previously Expected

23. apr 2026, 21:24 UTC

Tulu

SAP Stock Rebounds From Software Slaughter. The Cloud Boosted Europe's Tech Titan. -- Barrons.com

23. apr 2026, 21:24 UTC

Tulu

Blackstone Stock Falls After Earnings. Private Credit Remains in Focus. -- Barrons.com

23. apr 2026, 21:21 UTC

Tulu

Intel to Look for Unconventional Way to Boost Manufacturing Capacity Through Musk's Terafab Project, CEO Says

23. apr 2026, 21:21 UTC

Tulu

Intel CEO: He, Elon Musk Believe Global Semiconductor Supply Isn't Keeping Up With Accelerating Demand

Võrdlus sarnastega

Hinnamuutus

CorMedix Inc Prognoos

Hinnasiht

By TipRanks

76.9% tõus

12 kuu keskmine prognoos

Keskmine 13.25 USD 76.9%

Kõrge 14 USD

Madal 13 USD

Põhineb 5 Wall Streeti analüütiku instrumendi CorMedix Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

5 ratings

Osta

Hoia

Müü

Põhineb 5 analüütiku instrumendi CorMedix Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

9.2 / N/AToetus ja vastupanu

Recent bullish events outweigh bearish events.

All events are bullish.

Sentiment

By Acuity

178 / 348 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest CorMedix Inc

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.